Caggiano Anthony 4
Research Summary
AI-generated summary
Cognition Therapeutics CMO Anthony Caggiano Buys 10,000 Shares
What Happened
Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics, disclosed an open-market purchase of 10,000 common shares on April 16, 2026 at $1.11 per share, for a total purchase value of $11,100. This was a straight purchase (transaction code P), which is generally a direct buy of company stock rather than an option exercise or award.
Key Details
- Transaction date: 2026-04-16
- Price per share: $1.11; Shares acquired: 10,000; Total value: $11,100
- Transaction type: Purchase (code P) — reported as an open-market/private purchase on Form 4
- Shares owned after transaction: Not specified in the filing
- Filing date: 2026-04-20 (Form 4). Timing appears timely — Form 4 was filed within the normal 2-business-day window.
- No footnotes, 10b5-1 plan, tax withholding, or other special conditions disclosed in the filing
Context
- Company insiders buying shares is often seen as a more informative signal than routine sales, but this purchase is relatively small in dollar terms ($11.1k).
- The filing is informational; it does not state the insider’s motives. Retail investors should consider this alongside other filings, company fundamentals, and market conditions.